Navigation Links
China Cord Blood Corporation Updates Status Regarding Share Repurchase Program
Date:10/7/2010

HONG KONG, Oct. 7 /PRNewswire-Asia-FirstCall/ -- China Cord Blood Corporation ("CCBC" or "the Company") (NYSE: CO), the first and largest cord blood bank operator in China, today announced that since the authorization of the stock repurchase program on September 15, 2010, the Company has repurchased approximately 309,000 ordinary shares for approximately US$1.6 million through October 6, 2010 at an average price per share of US$5.32.  This amount represents approximately 10.7% of the total repurchase program authorized by CCBC's Board of Directors, with approximately US$13.4 million remaining in the Company's buyback authorization for repurchase prior to September 2011.

Ms. Ting Zheng, Chairperson and CEO of China Cord Blood Corporation, stated, "We are committed to enhancing shareholder value, and our actions in the past weeks demonstrate our commitment to our shareholders and management's confidence in the Company's business and future prospects.  We do not believe the current share price reflects the intrinsic value of the Company's business.  Our expansion plan in Zhejiang province that was announced in September, together with our intention to execute the warrant exchange offer to simplify our capital structure, should contribute to a stronger earnings profile.  We plan to continue to grow our existing business, and at the same time, seek opportunities to expand our business in China and the Asia Pacific region."

About China Cord Blood CorporationChina Cord Blood Corporation is the first and largest cord blood banking operator in China in terms of geographical coverage and is the only cord blood bank operator with multiple licenses.  Under the current PRC government regulations, only one licensed cord blood bank operator is permitted to operate in each licensed region and only seven licenses have been authorized as of today.  China Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services. For more information, please visit our website at http://www.chinacordbloodcorp.com.

Safe Harbor StatementThis press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events, performance and results of operations, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in statements filed from time to time with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the Company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof. For more information, please contact:China Cord Blood CorporationMs. Joeling LawPhone: +852-3605-8180Email: ir@chinacordbloodcorp.com ICR, LLCIn New York: Ashley M. Ammon or Christine DuanPhone: +1-646-277-1227In Beijing:Wen Lei ZhengPhone: +86-10-6599-7968
'/>"/>

SOURCE China Cord Blood Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. China Pharma Holdings, Inc. Successfully Completes Phase I Clinical Trials of New Anti-Drug-Resistance Antibiotic
2. China-Biotics Hosted its First Investor Day Event
3. Cord Blood America CEO Matthew Schissler Discusses Projects in China, South America, Afford-A-Cord, and Profitability
4. China Cord Blood Corporation to Launch Warrant Exchange Offer
5. China Cord Blood Corporation Reports First Quarter Fiscal 2011 Financial Results
6. China-Biotics Ranked Number 62 on FORTUNES 100 Fastest-Growing Companies List
7. Reportlinker Adds Advances in Biopharmaceutical Technology in China
8. China BCT Reports Strong Second Quarter 2010 Results
9. China Biologic Products Announces Record Second Quarter 2010 Results
10. China Biologic Products to Attend Canaccord Genuity 30th Annual Growth Conference
11. China BCT Further Expands its Footprint by Opening 12 New Retail Pharmaceutical Stores
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... LOS ANGELES , Feb. 23, 2017  Capricor Therapeutics, ... cardiac and other medical conditions, today announced that Linda Marbán, ... at two upcoming investor conferences: Cowen ... 2017 at 10:00 am ET Boston, MA ... 14, 2017 at 9:00 am PT (12:00 pm ET) ...
(Date:2/23/2017)... and SAN FRANCISCO , Feb. 23, ... medicine company, and Beyond Type 1, a not-for-profit advocacy ... diabetes, today announced a grant from Beyond Type 1 ... for type 1 and other insulin-requiring diabetes.  ... developing innovative stem cell-derived cell replacement therapies with a ...
(Date:2/22/2017)... LEAWOOD, Kan. , Feb. 22, 2017  Aratana Therapeutics, ... licensing, development and commercialization of innovative biopharmaceutical products for companion ... 14, 2017 at 8:30 a.m. ET to discuss financial results ... 2016. Interested participants and investors may access ... dial-in: ...
(Date:2/22/2017)... ... February 22, 2017 , ... Park Systems , ... AFM Luncheon for all SPIE attendees and Park customers on Feb. ... block from the San Jose Convention Center. The luncheon will feature a talk ...
Breaking Biology Technology:
(Date:2/7/2017)... --  MedNet Solutions , an innovative SaaS-based eClinical technology ... is pleased to announce that the latest release of ... and award winning eClinical solution, is now available for ... a proven Software-as-a-Service (SaaS) clinical research technology platform that ... delivers an entire suite of eClinical tools to support ...
(Date:2/3/2017)... , Feb. 3, 2017  Texas Biomedical Research Institute announced ... Larry Schlesinger as the Institute,s new President and ... effective May 31, 2017. He is currently the Chair of ... the Center for Microbial Interface Biology at Ohio State University. ... the new President and CEO of Texas Biomed," said Dr. ...
(Date:2/2/2017)... , Feb. 1, 2017  Central to ... and meaningful advances worldwide, The Japan Prize Foundation ... Prize, who have pushed the envelope in their ... and Communication. Three scientists are being recognized with ... achievements that not only contribute to the advancement ...
Breaking Biology News(10 mins):